Country: Kanada
Bahasa: Inggeris
Sumber: Health Canada
GALANTAMINE (GALANTAMINE HYDROBROMIDE)
MYLAN PHARMACEUTICALS ULC
N06DA04
GALANTAMINE
16MG
CAPSULE (EXTENDED RELEASE)
GALANTAMINE (GALANTAMINE HYDROBROMIDE) 16MG
ORAL
30/100
Prescription
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Active ingredient group (AIG) number: 0144660004; AHFS:
APPROVED
2011-11-12
Page 1 of 55 PRODUCT MONOGRAPH Pr MYLAN-GALANTAMINE ER Galantamine Hydrobromide Extended-Release Capsules 8 mg, 16 mg, 24 mg galantamine base Cholinesterase Inhibitor Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Revision: April 13, 2017 Submission Control No: 204535 Page 2 of 55 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 3 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS ................................................................................................. 14 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ............................................................................................................... 18 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 19 STORAGE AND STABILITY ......................................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 23 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 PHARMACEUTICAL INFORMATION ......................................................................... 25 CLINICAL TRIALS ......................................................................................................... 26 DETAILED PHARMACOLOGY ............................................... Baca dokumen lengkap